info@marketresearchfuture.com   ๐Ÿ“ž  +1 (855) 661-4441(US)   ๐Ÿ“ž  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major playersโ€™ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Biotechnology Contract Manufacturing Market Research Report Information By Service (Manufacturing, Formulation & Fill-Finish, Packaging & Labelling, and Other Services), By Type (Biologic Drug Substance Manufacturing and Biologic Drug Product Manufacturing), By Scale of Operation (Commercial Operations and Clinical Operations), By Source (Mammalian Expression Systems and Non-Mammalian Expression Systems), By Molecule (Monoclonal Antibodies, Cell Therapy & Gene Therapy, Antibody-Drug Conjugates (ADCs), Vaccines, Therapeutic Peptides & Protei


ID: MRFR/HC/20357-HCR | 128 Pages | Author: Rahul Gotadki| November 2024

Biotechnology Contract Manufacturing Market Segmentation


Biotechnology Contract Manufacturing Service Outlook (USD Billion, 2019-2032)




  • Manufacturing




  • Formulation and Fill-Finish




  • Packaging and Labeling




  • Other services




Biotechnology Contract Manufacturing Type Outlook (USD Billion, 2019-2032)




  • Biologic Drug Substance Manufacturing




  • Biologic Drug Product Manufacturing




Biotechnology Contract Manufacturing Scale of Operation Outlook (USD Billion, 2019-2032)




  • Commercial Operations




  • Clinical Operations




Biotechnology Contract Manufacturing Source Outlook (USD Billion, 2019-2032)




  • Mammalian Expression Systems




  • Non-Mammalian Expression Systems




Biotechnology Contract Manufacturing Molecule Outlook (USD Billion, 2019-2032)




  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types




Biotechnology Contract Manufacturing Therapeutic Area Outlook (USD Billion, 2019-2032)




  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas




Biotechnology Contract Manufacturing Regional Outlook (USD Billion, 2019-2032)




  • North America Outlook (USD Billion, 2019-2032)




    • North America Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • North America Biotechnology Contract Manufacturing by Source




      • Mammalian Expression Systems




      • Non-Mammalian Expression Systems






    • North America Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • North America Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • North America Biotechnology Contract Manufacturing by Molecule








  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • North America Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • US Outlook (USD Billion, 2019-2032)




    • US Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • US Biotechnology Contract Manufacturing by Source




      • Mammalian Expression Systems




      • Non-Mammalian Expression Systems






    • US Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • US Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • US Biotechnology Contract Manufacturing by Molecule







  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • US Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • CANADA Outlook (USD Billion, 2019-2032)




    • CANADA Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • CANADA Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • CANADA Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • CANADA Biotechnology Contract Manufacturing by Source







  • Mammalian Expression Systems






  • Non-Mammalian Expression Systems







    • CANADA Biotechnology Contract Manufacturing by Molecule




      • Monoclonal Antibodies




      • Cell Therapy & Gene Therapy




      • Antibody-Drug Conjugates (ADCs)




      • Vaccines




      • Therapeutic Peptides & Proteins




      • Other Molecule Types






    • CANADA Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas






  • Europe Outlook (USD Billion, 2019-2032)




    • Europe Biotechnology Contract Manufacturing by Service








  • Manufacturing






  • Formulation and Fill-Finish






  • Packaging and Labeling






  • Other services







    • Europe Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • Europe Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • Europe Biotechnology Contract Manufacturing by Source




      • Mammalian Expression Systems




      • Non-Mammalian Expression Systems






    • Europe Biotechnology Contract Manufacturing by Molecule




      • Monoclonal Antibodies




      • Cell Therapy & Gene Therapy




      • Antibody-Drug Conjugates (ADCs)




      • Vaccines




      • Therapeutic Peptides & Proteins




      • Other Molecule Types






    • Europe Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • Germany Outlook (USD Billion, 2019-2032)




    • Germany Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • Germany Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • Germany Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • Germany Biotechnology Contract Manufacturing by Source




      • Mammalian Expression Systems




      • Non-Mammalian Expression Systems






    • Germany Biotechnology Contract Manufacturing by Molecule







  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • Germany Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • France Outlook (USD Billion, 2019-2032)




    • France Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • France Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • France Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • France Biotechnology Contract Manufacturing by Source







  • Mammalian Expression Systems






  • Non-Mammalian Expression Systems







    • France Biotechnology Contract Manufacturing by Molecule







  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • France Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • UK Outlook (USD Billion, 2019-2032)




    • UK Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • UK Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • UK Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • UK Biotechnology Contract Manufacturing by Source







  • Mammalian Expression Systems




  • Non-Mammalian Expression Systems







    • UK Biotechnology Contract Manufacturing by Molecule







  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • UK Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • ITALY Outlook (USD Billion, 2019-2032)




    • ITALY Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • ITALY Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • ITALY Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • ITALY Biotechnology Contract Manufacturing by Source







  • Mammalian Expression Systems






  • Non-Mammalian Expression Systems







    • ITALY Biotechnology Contract Manufacturing by Molecule







  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • ITALY Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • SPAIN Outlook (USD Billion, 2019-2032)




    • Spain Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • Spain Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • Spain Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • Spain Biotechnology Contract Manufacturing by Source







  • Mammalian Expression Systems






  • Non-Mammalian Expression Systems







    • Spain Biotechnology Contract Manufacturing by Molecule







  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • Spain Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • Rest Of Europe Outlook (USD Billion, 2019-2032)




    • Rest Of Europe Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • Rest Of Europe Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • REST OF EUROPE Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • REST OF EUROPE Biotechnology Contract Manufacturing by Source







  • Mammalian Expression Systems






  • Non-Mammalian Expression Systems







    • REST OF EUROPE Biotechnology Contract Manufacturing by Molecule




      • Monoclonal Antibodies




      • Cell Therapy & Gene Therapy




      • Antibody-Drug Conjugates (ADCs)




      • Vaccines




      • Therapeutic Peptides & Proteins




      • Other Molecule Types






    • REST OF EUROPE Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas






  • Asia-Pacific Outlook (USD Billion, 2019-2032)




    • Asia-Pacific Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • Asia-Pacific Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • Asia-Pacific Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • Asia-Pacific Biotechnology Contract Manufacturing by Source




      • Mammalian Expression Systems




      • Non-Mammalian Expression Systems






    • Asia-Pacific Biotechnology Contract Manufacturing by Molecule








  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • Asia-Pacific Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • China Outlook (USD Billion, 2019-2032)




    • China Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • China Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • China Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • China Biotechnology Contract Manufacturing by Source




      • Mammalian Expression Systems




      • Non-Mammalian Expression Systems






    • China Biotechnology Contract Manufacturing by Molecule







  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • China Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • Japan Outlook (USD Billion, 2019-2032)




    • Japan Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • Japan Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • Japan Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • Japan Biotechnology Contract Manufacturing by Source




      • Mammalian Expression Systems




      • Non-Mammalian Expression Systems






    • Japan Biotechnology Contract Manufacturing by Molecule







  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • Japan Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • India Outlook (USD Billion, 2019-2032)




    • India Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • India Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • India Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • India Biotechnology Contract Manufacturing by Source




      • Mammalian Expression Systems




      • Non-Mammalian Expression Systems






    • India Biotechnology Contract Manufacturing by Molecule







  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • India Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • Australia Outlook (USD Billion, 2019-2032)




    • Australia Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • Australia Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • Australia Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • Australia Biotechnology Contract Manufacturing by Source




      • Mammalian Expression Systems




      • Non-Mammalian Expression Systems






    • Australia Biotechnology Contract Manufacturing by Molecule







  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • Australia Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2032)




    • Rest of Asia-Pacific Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • Rest of Asia-Pacific Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • Rest of Asia-Pacific Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • Rest of Asia-Pacific Biotechnology Contract Manufacturing by Source







  • Mammalian Expression Systems




  • Non-Mammalian Expression Systems







    • Rest of Asia-Pacific Biotechnology Contract Manufacturing by Molecule




      • Monoclonal Antibodies




      • Cell Therapy & Gene Therapy




      • Antibody-Drug Conjugates (ADCs)




      • Vaccines




      • Therapeutic Peptides & Proteins




      • Other Molecule Types






    • Rest of Asia-Pacific Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas






  • Rest of the World Outlook (USD Billion, 2019-2032)




    • Rest of the World Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • Rest of the World Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • Rest of the World Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • Rest of the World Biotechnology Contract Manufacturing by Source




      • Mammalian Expression Systems




      • Non-Mammalian Expression Systems






    • Rest of the World Biotechnology Contract Manufacturing by Molecule








  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • Rest of the World Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • Middle East Outlook (USD Billion, 2019-2032)




    • Middle East Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • Middle East Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • Middle East Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • Middle East Biotechnology Contract Manufacturing by Source




      • Mammalian Expression Systems




      • Non-Mammalian Expression Systems






    • Middle East Biotechnology Contract Manufacturing by Molecule







  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • Middle East Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • Africa Outlook (USD Billion, 2019-2032)




    • Africa Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • Africa Biotechnology Contract Manufacturing by Type




      • Biologic Drug Substance Manufacturing




      • Biologic Drug Product Manufacturing






    • Africa Biotechnology Contract Manufacturing by Scale of Operation




      • Commercial Operations




      • Clinical Operations






    • Africa Biotechnology Contract Manufacturing by Source







  • Mammalian Expression Systems






  • Non-Mammalian Expression Systems







    • Africa Biotechnology Contract Manufacturing by Molecule







  • Monoclonal Antibodies




  • Cell Therapy & Gene Therapy




  • Antibody-Drug Conjugates (ADCs)




  • Vaccines




  • Therapeutic Peptides & Proteins




  • Other Molecule Types







    • Africa Biotechnology Contract Manufacturing by Therapeutic Area







  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas







    • Latin America Outlook (USD Billion, 2019-2032)




    • Latin America Biotechnology Contract Manufacturing by Service




      • Manufacturing




      • Formulation and Fill-Finish




      • Packaging and Labeling




      • Other services






    • Latin America Biotechnology Contract Manufacturing by Type







  • Biologic Drug Substance Manufacturing




  • Biologic Drug Product Manufacturing







    • Latin America Biotechnology Contract Manufacturing by Scale of Operation







  • Commercial Operations






  • Clinical Operations







    • Latin America Biotechnology Contract Manufacturing by Source




      • Mammalian Expression Systems




      • Non-Mammalian Expression Systems






    • Latin America Biotechnology Contract Manufacturing by Molecule




      • Monoclonal Antibodies




      • Cell Therapy & Gene Therapy




      • Antibody-Drug Conjugates (ADCs)




      • Vaccines




      • Therapeutic Peptides & Proteins




      • Other Molecule Types









  • Latin America Biotechnology Contract Manufacturing by Therapeutic Area






  • Oncology




  • Autoimmune Diseases




  • Cardiovascular Diseases




  • Metabolic Diseases




  • Infectious Diseases




  • Neurology




  • Other Therapeutic Areas



Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3.Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2.Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porterโ€™s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE

6.1. Overview

6.2. Manufacturing

6.3. Formulation and Fill-Finish

6.4. Packaging and Labeling

6.5. Other services

7. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE

7.1. Overview

7.2. Biologic Drug Substance Manufacturing

7.3. Biologic Drug Product Manufacturing

8. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION

8.1. Overview

8.2. Commercial Operations

8.3. Clinical Operations

9. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE

9.1. Overview

9.2. Mammalian Expression Systems

9.3. Non-Mammalian Expression Systems

10. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE

10.1. Overview

10.2. Monoclonal Antibodies

10.3. Cell Therapy & Gene Therapy

10.4. Antibody-Drug Conjugates (ADCs)

10.5. Vaccines

10.6. Therapeutic Peptides & Proteins

10.7. Other Molecule Types

11. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA

11.1. Overview

11.2. Oncology

11.3. Autoimmune Diseases

11.4. Cardiovascular Diseases

11.5. Metabolic Diseases

11.6. Infectious Diseases.

11.7. Neurology

11.8. Other Therapeutic Areas

12. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY REGION

12.1. Overview

12.1. North America

12.1.1. US

12.1.2. Canada

12.2. Europe

12.2.1. Germany

12.2.2. France

12.2.3. UK

12.2.4. Italy

12.2.5. Spain

12.2.6. Rest of Europe

12.3. Asia-Pacific

12.3.1. China

12.3.2. India

12.3.3. Japan

12.3.4. South Korea

12.3.5. Australia

12.3.6. Rest of Asia-Pacific

12.4. Rest of the World

12.4.1. Middle East

12.4.2. Africa

12.4.3. Latin America

13. COMPETITIVE LANDSCAPE

13.1. Overview

13.2. Competitive Analysis

13.3. Market Share Analysis

13.4. Major Growth Strategy in the Global Biotechnology Contract Manufacturing,

13.5. Competitive Benchmarking

13.6. Leading Players in Terms of Number of Developments in the Global Biotechnology Contract Manufacturing,

13.7. Key developments and Growth Strategies

13.7.1. New Product Launch/Service Deployment

13.7.2. Merger & Acquisitions

13.7.3. Joint Ventures

13.8. Major Players Financial Matrix

13.8.1. Sales & Operating Income, 2023

13.8.2. Major Players R&D Expenditure. 2023

14. COMPANY PROFILES

14.1. Lonza (Switzerland)

14.1.1. Company Overview

14.1.2. Financial Overview

14.1.3. Products Offered

14.1.4. Key Developments

14.1.5. SWOT Analysis

14.1.6. Key Strategies

14.2. THERMO FISHER SCIENTIFIC, INC. (US)

14.2.1. Company Overview

14.2.2. Financial Overview

14.2.3. Products Offered

14.2.4. Key Developments

14.2.5. SWOT Analysis

14.2.6. Key Strategies

14.3. Catalent, Inc. (US)

14.3.1. Company Overview

14.3.2. Financial Overview

14.3.3. Products Offered

14.3.4. Key Developments

14.3.5. SWOT Analysis

14.3.6. Key Strategies

14.4. Samsung Biologics (South Korea)

14.4.1. Company Overview

14.4.2. Financial Overview

14.4.3. Products Offered

14.4.4. Key Developments

14.4.5. SWOT Analysis

14.4.6. Key Strategies

14.5. WuXi Bilogics (China)

14.5.1. Company Overview

14.5.2. Financial Overview

14.5.3. Products Offered

14.5.4. Key Developments

14.5.5. SWOT Analysis

14.5.6. Key Strategies

14.6. Boehringer Ingelheim International GmbH (Germany)

14.6.1. Company Overview

14.6.2. Financial Overview

14.6.3. Products Offered

14.6.4. Key Developments

14.6.5. SWOT Analysis

14.6.6. Key Strategies

14.7. FUJIFILM Holding Corporation (Japan)

14.7.1. Company Overview

14.7.2. Financial Overview

14.7.3. Products Offered

14.7.4. Key Developments

14.7.5. SWOT Analysis

14.7.6. Key Strategies

14.8. ABBVIE, INC. (US)

14.8.1. Company Overview

14.8.2. Financial Overview

14.8.3. Products Offered

14.8.4. Key Developments

14.8.5. SWOT Analysis

14.8.6. Key Strategies

14.9. Eurofins Scientific (Luxembourg)

14.9.1. Company Overview

14.9.2. Financial Overview

14.9.3. Products Offered

14.9.4. Key Developments

14.9.5. SWOT Analysis

14.9.6. Key Strategies

14.10. Merck KgaA (Germany) (US)

14.10.1. Company Overview

14.10.2. Financial Overview

14.10.3. Products Offered

14.10.4. Key Developments

14.10.5. SWOT Analysis

14.10.6. Key Strategies

14.11. AGC, Inc. (Japan)

14.11.1. Company Overview

14.11.2. Financial Overview

14.11.3. Products Offered

14.11.4. Key Developments

14.11.5. SWOT Analysis

14.11.6. Key Strategies

14.12. Merck KgaA (Germany)

14.12.1. Company Overview

14.12.2. Financial Overview

14.12.3. Products Offered

14.12.4. Key Developments

14.12.5. SWOT Analysis

14.12.6. Key Strategies

14.13. JSR Corporation (Japan)

14.13.1. Company Overview

14.13.2. Financial Overview

14.13.3. Products Offered

14.13.4. Key Developments

14.13.5. SWOT Analysis

14.13.6. Key Strategies

15. APPENDIX

15.1. References

15.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SYNOPSIS, 2019-2032

TABLE 2 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)

TABLE 3 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 4 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 5 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 6 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 7 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 8 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 9 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 10 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 11 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 12 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 13 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 14 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 15 US: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 16 US: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 17 US: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 18 US: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 19 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 20 US: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 21 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 22 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 23 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 24 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 25 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 26 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 1 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 2 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 3 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 4 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 5 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 6 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 7 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 8 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 9 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 10 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 11 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 12 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 13 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 14 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 15 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 16 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 17 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 18 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 19 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 20 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 21 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 22 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 23 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 24 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 25 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 26 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 27 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 28 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 29 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 30 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 31 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 32 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 33 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 34 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 35 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 36 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 37 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 38 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 39 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 40 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 41 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 42 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 43 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 44 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 45 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 46 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 47 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 48 ASIAPACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 49 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 50 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 51 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 52 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 53 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 54 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 55 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 56 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 57 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 58 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 59 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 60 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 61 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 62 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 63 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 64 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 65 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 66 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 67 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 68 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 69 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 70 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 71 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 72 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 73 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 74 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 75 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 76 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 77 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 78 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 79 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 80 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 81 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 82 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 83 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 84 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 85 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 86 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 87 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 88 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 89 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 90 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 91 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 92 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 93 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 94 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 95 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 96 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 97 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 98 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 99 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 100 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 101 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 102 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 103 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)

TABLE 104 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)

TABLE 105 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)

TABLE 106 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)

TABLE 107 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)

TABLE 108 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING

FIGURE 4 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY SERVICE, 2023

FIGURE 5 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY TYPE, 2023

FIGURE 6 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY SCALE OF OPERATION, 2023

FIGURE 7 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY SOURCE, 2023

FIGURE 8 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY MOLECULE, 2023

FIGURE 9 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY THERAPEUTIC AREA, 2023

FIGURE 10 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023

FIGURE 11 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023

FIGURE 12 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023

FIGURE 13 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023

FIGURE 14 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023

FIGURE 15 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 16 LONZA (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 LONZA (SWITZERLAND): SWOT ANALYSIS

FIGURE 18 THERMO FISHER SCIENTIFIC, INC. (US): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 THERMO FISHER SCIENTIFIC, INC. (US): SWOT ANALYSIS

FIGURE 20 CATALENT, INC. (US): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 CATALENT, INC. (US): SWOT ANALYSIS

FIGURE 22 SAMSUNG BIOLOGICS (SOUTH KOREA): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 SAMSUNG BIOLOGICS (SOUTH KOREA): SWOT ANALYSIS

FIGURE 24 WUXI BILOGICS (CHINA).: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 WUXI BILOGICS (CHINA).: SWOT ANALYSIS

FIGURE 26 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (GERMANY): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (GERMANY): SWOT ANALYSIS

FIGURE 28 FUJIFILM HOLDING CORPORATION (JAPAN): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 FUJIFILM HOLDING CORPORATION (JAPAN): SWOT ANALYSIS

FIGURE 30 ABBVIE, INC. (US): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 ABBVIE, INC. (US): SWOT ANALYSIS

FIGURE 32 EUROFINS SCIENTIFIC (LUXEMBOURG): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 EUROFINS SCIENTIFIC (LUXEMBOURG): SWOT ANALYSIS

FIGURE 34 AGC, INC. (JAPAN): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 AGC, INC. (JAPAN): SWOT ANALYSIS

FIGURE 36 MERCK KGAA (GERMANY): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 MERCK KGAA (GERMANY): SWOT ANALYSIS

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.